Introduction
============

A consistent body of literature concerning cognitive-behavioral alterations in amyotrophic lateral sclerosis (ALS) in the last 20 years allowed to recognize it as a multisystem disorder, and not a purely motor neuron disease. In particular, specific cognitive alterations have been described, together with psychological and behavioral changes, with underlying uncompletely determined patterns of neuroradiological, neurobiological, and genetic profiles ([@B15]; [@B30]; [@B18]; [@B2]). A prevalence of 30--50% of cognitive impairment, predominantly in the form of executive dysfunction, has been described ([@B30]; [@B27]); in about 10--15% of ALS patients these changes fulfill the criteria for frontotemporal dementia -- FTD ([@B30]; [@B18]; [@B27]). Prevalence rates for depression and anxiety in ALS range from 0 to 44% and from 0 to 30%, respectively ([@B23]). Both psychological aspects and cognitive changes exert a well-known effect on quality of life, functional abilities, prognosis and survival of patients with ALS (pALS) ([@B17]; [@B44]; [@B49]). An association between cognitive deficits and depression has been consistently observed in both clinical and medically healthy populations ([@B24]; [@B38]; [@B35]; [@B50]). In particular, depressive symptoms seem to primarily affect executive functioning, with neuroimaging findings supporting the involvement of brain networks entailing frontal-subcortical circuits in depressed patients ([@B38]; [@B3]; [@B9]).

Despite the presence of consistent evidence in other neurological diseases (e.g., [@B43]; [@B29]; [@B39]), the association between cognition and psychological aspects has been poorly investigated in ALS, also showing conflicting results. A recent study revealed the absence of a relation between cognitive impairment and psychiatric/psychosocial measures, as well as between cognitive impairment and wish to die, employing a neuropsychological assessment focused on executive functions ([@B36]). On the contrary, other studies adopting different measures of cognitive functions showed an association between psychological/psychiatric symptoms and global cognition ([@B47]) and between depression and specific neuropsychological aspects, including verbal and visual learning, processing speed and language ([@B20]).

When considering more innovative cognitive tools, two recent studies about feasibility of Eye-Tracking (ET) and Brain Computer Interface (BCI) technologies for cognitive testing in ALS highlighted a negative correlation between anxiety levels and reasoning time at some neuropsychological tests for executive functions. Such results were interpreted according to an increase in the rate of impulsivity, possibly depending both on the reduced amount of cognitive and inhibitory resources in pALS and on the supplementary influence of anxiety on such cognitive profile ([@B32],[@B33]). In both studies, no significant correlations were observed between ET tests and depression level, as measured by Beck Depression Inventory ([@B5]).

A relevant issue in the neuropsychological assessment of pALS concerns the absence of validated gold standard tools, accommodating for progressive physical disabilities and providing reliable, comprehensive and comparable results across studies. This aspect remained an unsolved issue till the recent development ([@B1]), and validation into several languages ([@B25]; [@B28]; [@B34]) of a rapid multi-domain cognitive-behavioral screening tool specifically designed for ALS, i.e., the Edinburgh Cognitive and Behavioral ALS Screen -- ECAS. Moreover, the ECAS has been specifically designed to accommodate for verbal/motor disability, since subtests can be administered both in spoken and written form and in moderate/advanced stages of the disease. Despite the rapid and large diffusion of such screening tool for the clinical assessment of pALS, it has never been applied in order to specifically investigate the association between cognitive and psychological aspects. Only two studies report the use of the ECAS in association to psychological and behavioral scales, without specifically addressing such topic. In particular, [@B37] described the absence of correlation between depression evaluated by means of Geriatric Depression Scale and 'cognitive functioning task performances' including the Verbal Fluency Total Score of the ECAS. Another study ([@B28]) described the absence of correlations between anxiety and ECAS scores, but no indications were provided about symptoms of depression.

In the context of the validation of the Italian ECAS, we preliminarily explored the relationship between such instrument and psychological variables such as anxiety and depression ([@B34]). In the recruited sample, a mild negative association was observed between depression assessment and both global and ALS-specific functions scores at the ECAS; moreover, state anxiety assessment negatively correlated with the ECAS total and the ALS non-specific functions scores.

As above described, previous literature data on other medically ill and non-medically ill populations ([@B43]; [@B24]; [@B38]; [@B29]; [@B39]; [@B35]; [@B50]) supports the presence of a relationship between a psychological aspect, i.e., presence/severity of depressive symptoms and cognitive profiles. Basing on such evidence, as well as on conflicting results regarding pALS and on our preliminary findings, we aimed to investigate the association between psychological features and cognitive abilities with the ECAS in a larger ALS population, particularly focusing on executive functions. Such association was also investigated with traditional cognitive measures of frontal (FAB) and global cognitive functioning (MoCA) not specifically designed for ALS, in order to identify possible differences between the gold standard ALS instrument and traditional cognitive tools for such purposes.

The presented research is part of a larger and ongoing clinical study using the ECAS for longitudinal assessment, evaluating its feasibility and sensitivity across the course of ALS disease.

Materials and Methods {#s1}
=====================

Participants
------------

Sample included 168 ALS patients (Males: 114; Females: 54; age: 62.3 ± 12.1 years; education: 11.1 ± 4.4 years; disease duration: 33.6 ± 42.7 months) recruited at the Department of Neurology, IRCCS Istituto Auxologico Italiano. The diagnosis of ALS was made by neurologists experienced in the field of neuromuscular diseases, with patients fulfilling the revised El Escorial criteria for clinically possible, probable, probable -- laboratory-supported or definite ALS ([@B10]). Patients in terminal stages of disease or with major comorbid medical, neurological or cardio-vascular diseases were excluded from the study. Disease status was evaluated using the ALS Functional Rating Scale-Revised -- ALSFRS-R ([@B11]). The study protocol was reviewed and approved by the Ethics Committee of our Institution and all eligible subjects received verbal and written information about the study. All participants signed an informed consent, according to the Declaration of Helsinki. Patients performed the designed cognitive and psychological protocol, as described below; it was administered by trained neuropsychologists and required approximately 40 min.

Cognitive and Psychological Assessment
--------------------------------------

### Cognitive Assessment

A neuropsychological and psychological protocol employed in a previous study ([@B34]) was adopted, including both two standard cognitive measures and a recently validated rapid cognitive-behavioral screening tool specifically developed for ALS (Edinburgh Cognitive and Behavioral ALS Screen -- ECAS).

The Italian version of the ECAS was administered, assessing different cognitive domains, including ALS-specific (executive functions, fluency and language tests) and ALS non-specific domains (memory and visuospatial functions tests). Each domain includes specific tests (see **Table [1](#T1){ref-type="table"}**). Moreover, it involves a separate Carer Interview, investigating behavior and psychotic alterations.

###### 

pALS' scores at the standard cognitive screening and the ECAS.

                                 Mean ±*SD*      Range     Cut-off
  ------------------------------ --------------- --------- ---------
  FAB (*n* = 149)                15.81 ± 1.68    10--18    13.4
  MoCA (*n* = 143)               22.78 ± 2.86    14--30    17.36
  ECAS total score (*n* = 168)   99.67 ± 18.73   31--129   97
  ALS specific functions         73.24 ± 15.12   21--97    71
  Language functions             23.30 ± 4.19    9--28     22
  Naming                         6.64 ± 1.59     0--8      --
  Comprehension                  7.57 ± 0.83     4--8      --
  Spelling                       9.09 ± 2.83     0--12     --
  Fluency                        16.01 ± 5.75    0--24     14
  Fluency letter S               8.39 ± 3.01     0--12     --
  Fluency letter C               7.62 ± 3.57     0--12     --
  Executive functions            33.93 ± 7.59    9--47     31
  Reverse digit span             5.32 ± 1.87     0--11     --
  Alternation                    9.70 ± 3.36     0--12     --
  Sentence completion            9.36 ± 2.56     0--12     --
  Social cognition               9.55 ± 2.97     1--12     --
  ALS non-specific functions     26.43 ± 5.00    10--34    24
  Memory functions               15.05 ± 4.59    1--22     13
  Immediate recall               5.24 ± 2.10     0--9      --
  Delayed retention              7.69 ± 2.68     0--10     --
  Delayed recognition            2.11 ± 1.26     0--4      --
  Visuospatial functions         11.38 ± 1.02    6--12     10
  Dot counting                   3.90 ± 0.30     3--4      --
  Cube counting                  3.58 ± 0.80     1--4      --
  Number location                3.90 ± 0.39     1--4      --
                                                           

Data are expressed as Means ± SD or absolute numbers

.

Standard cognitive measures included two brief batteries; for frontal executive functions, Frontal Assessment Battery -- FAB ([@B16]) was employed, evaluating subdomains of conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy; for global cognitive functioning, Montreal Cognitive Assessment -- MoCA (Italian translation by [@B31]; Italian normative data by [@B13]) was administered.

### Psychological Assessment

The evaluation of depressive and anxiety symptoms was performed by means of two self-rated measures widely used in ALS, i.e., the *Beck Depression Inventory* (BDI) ([@B5]) and *State-Trait Anxiety Inventory-Y* (STAI-Y) ([@B40]), for both state (STAI-Y1) and trait (STAI-Y2) anxiety components assessment. The BDI consists of 21 items, concerning both cognitive-affective (BDI CA, items 0--13) and somatic-performance (BDI SP, items 14--21) symptoms of depression. Total score ranges from 0 to 63, with higher total scores indicating more severe depressive symptoms. The standard cut-off ranges are as follows: 0--9 indicates minimal depression, 10--18 indicates mild depression, 19--29 indicates moderate depression, 30--63 indicates severe depression. The 40-item STAI-Y scores range from 20 to 80. Questions refer to how anxious people are feeling at the time of the study (state) and in general (trait). Scores higher than 65 indicate a clinically relevant anxiety.

Statistical Analysis
--------------------

Descriptive statistics (mean ± standard deviations for continuous variables and absolute number and frequencies for discrete variables) were used to describe the main characteristics of our sample and performances obtained at the ECAS and at standard cognitive/psychological assessments. *Pearson's correlation coefficient* was used to assess the degree of association between measures. An α level of 0.05 was used for all hypothesis tests. *P*-values were adjusted with a 'False Discovery rate' approach for multiple comparison correction ([@B6]). All data analyses were performed using SAS 9.2 software (SAS Institute, Cary, NC, United States).

Results
=======

Patients' Demographic and Clinical Characteristics
--------------------------------------------------

Clinical neurological examination showed a mean ALSFRS/R score of 37.2 ± 7.5 (ALSFRS/R Bulbar: 10.2 ± 2.3); 51 patients presented upper limb regions involvement at onset, 70 lower limb regions, 9 upper and lower limb, 35 bulbar, 2 bulbar and lower limb and one respiratory symptoms at onset. Ten patients had non-invasive ventilation (NIV) and no one had percutaneous endoscopic gastrostomy (PEG). For description of patients' scores at ECAS and standard cognitive screening measures, see **Table [1](#T1){ref-type="table"}**.

With regard to psychological aspects, of the 154 patients who completed the BDI, one hundred (65%) showed a clinically significant depression, ranging from mild-to-moderate (43%), moderate-to-severe (17%) and severe (5%). Of the 155 patients who completed the STAI-Y, 13 (8%) showed a clinically significant state anxiety and 15 (10%) showed relevant trait anxiety levels. See **Table [2](#T2){ref-type="table"}** for description of patients' scores at the psychological assessment.

###### 

pALS' scores at the psychological assessment.

                                                           Mean ±*SD*      Range
  -------------------------------------------------------- --------------- --------
  **Beck Depression Inventory (BDI) (*n* = 154)**                          
  Total score                                              14.13 ± 8.84    1--58
  Cognitive-affective symptoms                             6.49 ± 5.95     0--41
  Somatic-performance symptoms                             7.64 ± 3.92     0--18
  **State-Trait Anxiety Inventory (Form Y) (*n* = 155)**                   
  State anxiety -- Y1 (*T*-score)                          49.46 ± 9.47    34--76
  Trait anxiety -- Y2 (*T*-score)                          50.92 ± 10.25   30--80
                                                                           

Data are expressed as Means ± SD or absolute numbers.

Relationship of Psychological Symptoms to ECAS Scores and Subdomains
--------------------------------------------------------------------

Analysis of association between cognitive and depression scores revealed the presence of significant, even if modest, correlations between variables. In particular, depression assessment negatively correlated with the ECAS Total and the ALS-Specific functions scores, mainly with regard to Somatic-Performance symptoms and BDI Total score (BDI SP-ECAS Total score: *r* = --0.21, *p* = 0.023; ALS-Specific functions score: *r* = --0.22, *p* = 0.019; BDI Total score-ECAS Total score: *r* = --0.22, *p* = 0.019; ALS-Specific functions score: *r* = --0.23, *p* = 0.019; BDI CA-ECAS Total score: *r* = --0.19, *p* = 0.028; ALS-Specific functions score: *r* = --0.19, *p* = 0.027). No significant correlations were observed between anxiety and the ECAS, concerning both Total score and ALS-non Specific/Specific functions.

Analysis performed on the ECAS subdomains revealed mild significant, negative correlations between the ECAS executive functions subdomain and both Cognitive-Affective and Somatic-Performance symptoms of depression (BDI CA-ECAS executive functions: *r* = --0.21, *p* = 0.023; BDI SP-ECAS executive functions: *r* = --0.24, *p* = 0.017). Moreover, negative correlations were also observed between BDI total score and Executive functions subdomains as well as Language (BDI Total score-ECAS Language: *r* = --0.20, *p* = 0.023; ECAS executive functions: *r* = --0.25, *p* = 0.016). Language subdomain also correlated with Cognitive-Affective BDI subscore (*r* = --0.19, *p* = 0.027).

### Relationship of Psychological Symptoms to Specific Cognitive Tests of the ECAS Subdomains

Further analysis performed on cognitive tests included in the subdomains revealed that, with regard to executive functions subdomain, Sentence Completion and, particularly, Social Cognition were associated with depression levels measured by BDI total score and Somatic-Performance symptoms scores (BDI SP-Sentence Completion: *r* = --0.22, *p* = 0.019; Social Cognition: *r* = --0.29, *p* = 0.007; BDI Total score-Sentence Completion: *r* = --0.20, *p* = 0.023; Social Cognition: *r* = --0.26, *p* = 0.016). Mild correlations were also observed between Cognitive-Affective BDI subscore and Social Cognition (*r* = --0.19, *p* = 0.028). Moreover, BDI Total Score negatively correlated with performance at the Spelling test (BDI Total score-Spelling: *r* = --0.20, *p* = 0.028). Finally, significant but weak correlations were also observed between depression scores and Immediate Recall subtest within the Memory subdomain (BDI SP -- Immediate recall: *r* = --0.16, *p* = 0.044; BDI Total Score-Immediate Recall: *r* = --0.18, *p* = 0.029).

Relationship of Psychological Symptoms to Performance at Standard Cognitive Screening Tools
-------------------------------------------------------------------------------------------

No significant correlations were observed between depression assessment (BDI), concerning both total, cognitive-affective and somatic-performance symptoms, and traditional screening of frontal abilities (FAB) and global cognition (MoCA). Similarly, anxiety assessment (STAI-Y) did not correlated with either FAB or MoCA for neither state or trait anxiety scores.

Discussion
==========

This study revealed the presence of mild significant correlations between depression scores and the ECAS, mainly concerning the executive functions subdomain. Such findings are in accordance with previous literature regarding patients with depression without neurological illness. In particular, some recent reviews and meta-analysis about cognitive impairment in depressed patients showed that depression is related to reduction in a wide range of cognitive abilities, including attention, processing speed, executive function, and memory ([@B24]; [@B8]; [@B3]); in particular, larger impairments were observed in executive abilities concerning processing speed and shifting, while memory scores were affected by small to moderate impairments ([@B3]). A recent review on adult individuals with depression focusing on studies employing neuropsychological tests for executive functions showed that the majority of studies included (25 of 28) found alterations in some aspects of executive functioning in patients with depression ([@B4]). Moreover, deficit in executive functions and attention seem to persist after remission of depressive symptoms, in particular with regard to inhibition, shifting and verbal fluency ([@B38]; [@B3]).

In our sample, more detailed analysis within the executive functions subdomain revealed a more significant involvement of social cognition abilities in association with depression scores. Such finding is in agreement with literature underling a positive relationship between severity of depression symptoms and degree of Theory of Mind (ToM) impairments in depressed patients ([@B14]; [@B7]). In a recent meta-analysis, ToM deficits were not influenced by severity of executive dysfunctions, suggesting that social cognition impairment could represent a separate domain affected in depressive disorders, aside with executive functions ([@B7]). Debate is still open about the source of social cognition deficits in ALS as studies provide heterogeneous results about their independence from executive dysfunction ([@B12]; [@B41]). Another possible explanation is the one considering the inhibitory component as specifically associated to depression symptoms in ALS, resembling what described in depressed patients without neurological illness ([@B4]). In our sample, such consideration is supported by the association between depression scores and tasks markedly involving inhibitory abilities, i.e., Sentence Completion and Social Cognition within the Executive Functions subdomain.

Weak correlations have been observed in our sample between memory subdomain, in particular the Immediate Recall test, and depression scores. The involvement of memory functions, in particular immediate recall, cannot be clearly separated by the influence of attention and executive alterations, since available cognitive tests, and also those included into the ECAS, are usually related to both cognitive domains. In ALS population, the lack of consensus about the characterization of memory alterations and the poor specificity of such components leaded to not include them in the current criteria for ALS-FTD ([@B41]). Therefore, the collected data do not actually support an association between depression and memory function in our sample, also according to the weak correlations recorded.

Mild correlations have also been observed between the Spelling test within the language subdomain and depression score. Such data, not confirmed by available literature, needs further investigations and more significant data to be more critically considered.

Only few studies have investigated the association between depression symptoms and cognition in pALS. With regard to available literature in this field, our data are globally in accordance with two previous studies ([@B20]; [@B47]), highlighting an effect of depressive symptoms on cognitive performance at both global and specific neuropsychological measures in ALS. Conversely, contrasting results have been observed in other previous studies employing both traditional and motor-verbal free cognitive testing, showing the absence of a relationship between cognitive impairment and depression levels ([@B32],[@B33]; [@B36]). The novelty of such topic in ALS, in association with the variety of measures for depression and cognition employed and the different modes of administration of neuropsychological tests (both 'paper and pencil' and motor-verbal free based measures), makes a comparison with previous findings not feasible. Possibly, the increasing adoption of a recently validated gold standard measure for cognition and behavior in ALS, i.e., the ECAS, will allow to provide comparable data across studies and to realize longitudinal investigations, due to the partial compensation of motor disability. Moreover, the absence of correlations observed between depression scores and performance at standard cognitive screening tools (FAB and MoCA) further support the use of the ECAS for the investigation of the discussed topic according to both sensitivity and feasibility components of such instrument in ALS. In our sample, association with cognition mainly concerned Total BDI Score and Somatic-Performance BDI components, while Cognitive-Affective components were only poorly associated with cognitive scores. These results could be controversial, according to doubts that BDI may overestimate the presence of depression in ALS, since it contains a number of somatic/vegetative symptoms that can overlap with physical illness. However, the use of BDI in our protocol is consistent with previous studies that confirmed the reliability of such measure in pALS. A previous study comparing the estimated prevalence of depression using BDI and a questionnaire specifically designed for pALS revealed little discrepancy between findings ([@B22]). Also the use of a modified BDI scale, without items that could be confounded by physical symptoms, showed good agreement with the standard BDI scale ([@B48]). Therefore, the BDI score can be considered appropriate for clinical use in ALS population ([@B22]; [@B48]; [@B42]).

In depressed patients, both somatic/vegetative symptoms and negative affective states/dysfunctional cognitive patterns may interfere with optimal performance. According to our results, we could hypothesize that in pALS the influence of depression over cognition, in particular social cognition abilities, may be more specifically mediated by somatic/vegetative symptoms. If confirmed by further studies, this result could be discussed within the frame of psychophysiological changes, involving the sympathetic nervous system, observed in ALS in association to social and emotional impairments ([@B26]).

With regard to another psychological components investigated, i.e., state and trait anxiety, we found not significant associations with cognitive performances at the ECAS. According to recent literature, experimentally induced anxiety seems to impair performance only under low-load, i.e., simple cognitive tasks, while its effect is reduced when subjects engage in more difficult tasks that involve high attentional and executive resources ([@B45], [@B46]). Previous results obtained in ALS underlined an effect of anxiety on reasoning times, with higher levels of anxiety corresponding to lower execution times at some cognitive tests ([@B32],[@B33]). In our sample, the limited proportion of patients presenting with clinically relevant state and trait anxiety levels, with global mean scores considerably lower than cut off, could explain the absence of clear effects of such psychological component over the observed performances. Moreover, previously reported associations between anxiety and execution times would not have been observed with the employed protocol that not include time-related measures. Therefore, further investigations are needed in ALS in order to clarify such issue.

Limitations of the present study mainly concern the psychological evaluation of pALS. In particular, informations about previous depressive episodes that could have helped in distinguishing between recurrent depressive episodes and depressive symptoms reactive to ALS diagnosis have not been systematically collected and described. Moreover, exclusion of patients taking psychotropic drugs, or distinction of such subgroup for data analysis, would have been useful to prevent or highlight the potential effect of medications on cognitive performances.

Even if assessed in a large sample of pALS, the relationship between psychological factors and executive functions in such population cannot be considered fully clarified. Probably, the investigation about the complexity of factors modulating executive functions will benefit from the fully control of psychological variables, verbal-motor components of cognitive tests and other well-known aspects influencing cognitive performances (i.e., socio-demographic variables).

Despite the above mentioned limitations, if confirmed by further investigations and by stronger statistical results, the observed association between depression and executive functions could help to better plan both cognitive assessment/training and psychological interventions in ALS. With regard to the former, to emphasize the importance of a careful screening for depression could help to avoid a cognitive involvement overestimation. Furthermore, the observed correlation could mask the progression of cognitive involvement as measured in longitudinal assessments. Such point should be targeted in future follow-up studies with the ECAS. With regard to psychological interventions, the explanation about how comorbid cognitive impairment, as well as other biopsychosocial factors, moderate both pharmacotherapy and psychotherapy outcomes in ALS could turn into more tailored and effective interventions. Actually, due to the poor definition of the influence between cognitive and psychological aspects in ALS, cognitive alterations are mostly not considered in psychological interventions in ALS ([@B19]). Additionally, the influence of psychotherapy on cognitive aspects of pALS should be more deeply investigated, according to recent literature showing an association between changes in the central nervous systems, i.e., an attenuation in disease progression, and a concomitant psychological treatment ([@B21]).

The presented work could represent an important step toward the definition of a integrated approach to intervention for pALS, in accordance with the biopsychosocial model, with the aim to carefully and more efficiently manage such complex disease.
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